FDA Approves Long-acting RSV Antibody: A Major Medical Breakthrough Introduction The US Food and Drug Administration (FDA) has recently approved AstraZeneca and Sanofi’s nirsevimab (Beyfortus) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in neonates, infants, and young children. This approval marks a significant medical breakthrough in the fight against […]
CDC Recommends Pricey RSV Protection The Centers for Disease Control and Prevention (CDC) has recently recommended a new respiratory syncytial virus (RSV) antibody for infants, as well as a second shot for toddlers at risk of severe disease. This recommendation comes after a unanimous vote by the CDC‘s vaccine advisers. This is the first time […]
